David Weinstein

David Weinstein has taken on roles of increasing responsibility since joining Vividion in 2017. His scientific contributions have resulted from collaborations in compound library design and expansion, establishing a targeted protein degradation platform, and optimizing screening hits to candidates for drug development. As Vice President of Chemistry, Dave is responsible for ensuring that the departments of medicinal and computational chemistry and drug metabolism and pharmacokinetics (DMPK) contribute to advancing high quality molecules from across the portfolio of Vividion targets to patients.

Prior to joining Vividion, Dave led medicinal chemistry teams and drug discovery working groups at Bristol-Myers Squibb in Princeton, NJ for 18 years. He and his teams were responsible for delivering multiple candidate compounds into clinical development, including SotyktuTM (deucravacitinib), an allosteric TYK2 inhibitor which is now approved for the treatment of plaque psoriasis and which is being evaluated for utility in other autoimmune indications. Dave received his BS in Chemistry from UCLA and his PhD from Scripps Research. He is an inventor of 30 issued patents and has co-authored 24 papers.